Boehringer Ingelheim had begun construction of a new production facility for innovative drugs with an investment of US$99 million.
The new production facility will focus on the development activities for drugs in tablet form and manufacture them across the globe.
The facility will be capable for modern and flexible production and also helps to market new, innovative drugs.
It will be started in 2020 and 75 employees will develop new production methods for tablet preparations.
The new tablet production facility will continue to manufacture drugs that require highly complex production technologies.
The production facility is expected to operational by 2022.
|To be operational by 2022